Mediworld Middle East’s Post

Biofourmis Chief Operating Officer Jaydev Thakkar will be in Basel, Switzerland on June 26 for the 7th annual Digital Biomarkers in Clinical Trials Summit to participate in a panel discussion on digital biomarkers in Oncology. Thakkar will join leaders from Roche, Johnson & Johnson Innovative Medicine, and Evinova to go beyond the more established field of measuring activity levels and motor symptoms with digital health tools, to discuss what additional measurement approaches are being explored within Oncology. Heading to Basel? Send us a message! We’d love to share more about how our pharma partners are leveraging our enterprise platform and device ecosystem to advance cancer research and development. https://lnkd.in/drySvksT I #DigitalBiomarkers #Oncology #DigitalClinicalTrials #ClinicalTrials #DigitalHealth

As #BreastCancerAwareness Month comes to a close, let’s take a look at how far treatment has come—and the promising path ahead. Thanks to continued R&D, we’re seeing breakthroughs in early detection and targeted treatments that have made a real difference in patient outcomes, giving us powerful new tools to improve outcomes. Today, molecular profiling enables treatments tailored to each patient, while non-invasive liquid biopsies provide precise disease monitoring without the need for invasive procedures. It’s all helping to make a genuine difference. Leading researchers and executives are dedicated to making these developments possible. Daniel O'Day and Gilead Sciences, through Immunomedics, have introduced Trodelvy—an antibody-drug conjugate that’s offering new hope for those with metastatic triple-negative breast cancer. Meanwhile, Vas Narasimhan and the team at Novartis are leading research into novel biomarkers, promising earlier diagnosis and more customized therapies. And Eric Lefkofsky at Tempus AI has set a new standard with AI-driven data analysis, which is rapidly expanding our ability to personalize treatments at scale. It’s exciting to think about the future of precision medicine and how these advancements could reshape cancer care, getting us closer to a time when every patient receives the most effective treatment possible. #BreastCancerAwareness #CancerResearch #PrecisionMedicine #Innovation #Biotech

We are officially launching our new Residual Acute Myeloid (RAM) Application, expanding our oncology portfolio to support measurable residual disease (#MRD) capabilities. Our new solution will help monitor cancer and stay ahead of relapse, and it will be available to customers worldwide starting this July. Customers using the SOPHiA DDM TM RAM Solution will have access to longitudinal variant monitoring, allowing them to visualize the mutational landscape for each patient and its evolution over time. Our solution also provides users with the most up-to-date databases and customizable reporting features to generate graphical representations and comprehensive MRD reports. “AML (Acute Myeloid Leukemia) unfortunately still remains an area of high unmet medical need today, with associated suboptimal patient outcomes. MRD measurement and monitoring has a critical role to play, for example by enabling research into the most optimal sequencing of therapies,” said Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. Learn more: https://loom.ly/yzYkk6Q #DataDrivenMedicine #Oncology #AML #SOPHiADDM

Very excited to see the data from our collaboration with Jacob Berchuck and the team Dana-Farber Cancer Institute presented at #ESMO24 “Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform” 👉 https://lnkd.in/eYKWZB4c There is already one approved “blockbuster” medicine targeting PSMA and there are at least 30 more in development. Knowing whether a patient is PSMA+ve (established using PET with a PSMA specific tracer) is a requirement to Rx the one approved medicine, and it’s likely to play an important role in the future given its inclusion in many ongoing trials. Having a blood test would make it so much easier to find all of the eligible patients in practice. And there’s more data to come, including data that examine the link between determination of tumor PSMA expression using our platform and treatment outcome (and how that compares to the link between PET for PSMA and treatment outcome). What makes the clinical potential of our platform stand out even more is our ability to reveal additional high impact drug targets from the same blood test, creating the opportunity to enable precision use of medicines in a truly minimally invasive and accessible way 🩸 #cancerresearch #prostatecancer #ESMO #healthcare #liquidbiopsy #epigenomics Precede Biosciences

An Indian team of researchers led by scientist and geneticist Dr. Amit Dutt found that a novel fusion transcript is a promising therapeutic target for head and neck cancer AND that a FDA-approved deworming drug called pyrvinium pamoate could be a potential drug to treat such cancer. NPJ Precision Oncology journal published the results.    With promising results from animal studies, this team of researchers is planning to soon undertake clinical trials in oral cancer patients.    DiagnoSearch wholeheartedly welcomes this medical breakthrough. Oral cancer is the most predominant form of cancer among Indian patients. About 200,000 new cases are reported every year.   As a valuable partner to our sponsors and investigators for close to three decades and having supported studies in oncology, Team DiagnoSearch understands the critical role of high-quality clinical trials in bringing innovative healthcare solutions to society.      We wish the Indian Team much success in their clinical research journey!   #TheDiagnoSearchView . . #oncology #cancerawareness #healthcare #medicalresearch #clinicaltrials #clinicalresearch

Friday, April 12th, the #𝐅𝐃𝐀’𝐬 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐢𝐜 𝐃𝐫𝐮𝐠𝐬 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐂𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐞 𝐯𝐨𝐭𝐞𝐝 𝟏𝟐 𝐭𝐨 𝟎 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐭𝐨𝐭𝐚𝐥𝐢𝐭𝐲 𝐨𝐟 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐝𝐚𝐭𝐚 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐭𝐡𝐞 𝐮𝐬𝐞 𝐨𝐟 𝐦𝐢𝐧𝐢𝐦𝐚𝐥 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 (#𝐌𝐑𝐃) 𝐚𝐬 𝐚𝐧 𝐞𝐧𝐝 𝐩𝐨𝐢𝐧𝐭 𝐟𝐨𝐫 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐨𝐟 𝐧𝐞𝐰 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 #𝐦𝐲𝐞𝐥𝐨𝐦𝐚. Sebia’s CEO, Jean Marc Chermette touts, “This is a tremendous advance for patients with multiple myeloma, enabling investigators and biopharma companies to get much needed new promising agents made available and accessible. MRD plays a major role in the care of myeloma patients and having an analytically validated blood-based MRD assay such as M-inSight will serve a crucial need and spare having to perform for bone marrow biopsies”. #Sebia congratulates Representatives from The University of Miami’s Sylvester Comprehensive Cancer Center and the i2TEAMM who presented three independent data sets from a meta-analysis based on patient-level data from several clinical trials. The level of rigor of these analyses are superb and sets a new standard for biomarker development in oncology. ➡️ Visit https://lnkd.in/eXd5eNkT to learn more about M-inSight! #Minimalresidualdisease #Multiplemyeloma #MinSight

Pioneering Therapeutic Innovation: Highlights from the First hashtag #THRPTX Summit in Paris-Saclay After months of preparation, we're thrilled to reflect on this groundbreaking symposium that brought together today over 200 international experts, decision-makers, and healthcare professionals at our R&D Institute in Paris-Saclay. 🌍 Global Collaboration: THRPTX united brilliant minds from across the globe, fostering dialogue and collaboration that transcends borders in the pursuit of therapeutic innovation. 🧬 Scientific Excellence: Under the patronage of Nobel Laureate Prof. William G. Kaelin Jr., we explored cutting-edge innovations in oncology, from diagnosis to post-cancer care, and the profound impact of medical advancements on society. 🤝 Cross-disciplinary Synergy: The summit exemplified the power of cross-functionality, leveraging the Paris-Saclay ecosystem to accelerate R&D effectiveness and drive forward-thinking solutions in healthcare. 🔬 Patient-Centric Innovation: Discussions centered on patient needs, highlighting our commitment to developing therapies that positively impact patients' lives and their families. 💡 Future-Focused Dialogue: From AI and digital tools to the role of health data, we delved into the future of medical practices and society's expectations for health innovation. A special moment was the engaging exchange between Prof. Kaelin and Selena Bouffette, a Servier doctoral student representing our SHINEDocs community – bridging generations of scientific talent. Heartfelt thanks to Olivier Laureau, Claude Bertrand, and all the speakers, participants, and organizers who made THRPTX a resounding success. This summit reaffirms our position as a key player in global health innovation. As we look ahead, we're excited to continue driving therapeutic breakthroughs that will shape the future of healthcare and science. #TherapeuticInnovation #oncology #AI #MovedByYou #WeAreServier

#TuesdayClinicalInsights: Unlocking Potential in #LungCancer Research 📈  From designing clinical trials to better understanding clinical outcomes, the possibilities the LynxCare's European datasets have to offer are limitless. Unlocking New Possibilities for Pharma with our Lung Cancer datasets. 1️⃣ Our granular and quality-controlled real-world dataset can help design clinical trials that better reflect real-world scenarios. 2️⃣ The dataset can be leveraged to create synthetic control arms which can be used to evaluate the effectiveness of new lung cancer treatments. 3️⃣ Market Access and HEOR teams can gain a better understanding of the market and generate granular value dossiers. 4️⃣ Medical Affairs teams can obtain a better understanding of the clinical outcomes and real-world evidence associated with their lung cancer products. 5️⃣ Ready to explore more possibilities? ➡️ https://lnkd.in/ekghQVJW * 𝘓𝘺𝘯𝘹𝘊𝘢𝘳𝘦 𝘥𝘢𝘵𝘢𝘴𝘦𝘵𝘴 𝘤𝘰𝘯𝘤𝘦𝘳𝘯 𝘥𝘢𝘵𝘢𝘴𝘦𝘵𝘴 𝘸𝘪𝘵𝘩𝘪𝘯 𝘵𝘩𝘦 𝘓𝘺𝘯𝘹𝘊𝘢𝘳𝘦 𝘩𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘯𝘦𝘵𝘸𝘰𝘳𝘬. 𝘛𝘩𝘦 𝘩𝘰𝘴𝘱𝘪𝘵𝘢𝘭𝘴 𝘢𝘳𝘦 𝘵𝘩𝘦 𝘥𝘢𝘵𝘢 𝘤𝘰𝘯𝘵𝘳𝘰𝘭𝘭𝘦𝘳𝘴. 

Looking forward to this upcoming webinar! When hybrid AI's impact leads to improved #patientoutcomes, it's truly inspiring and fills me with immense pride. Join our experts this Thursday at 3pm CEST/9am ET to learn more about the power of AI in lifescience and the case study in oncology. Register here: https://hubs.la/Q02qfP4P0 #AI #DataInsights #oncology #biotech #innovationteams #lifescience

This year’s ESMO - European Society for Medical Oncology Congress 2024 was the largest ever, drawing in more than 33,000 𝐚𝐭𝐭𝐞𝐧𝐝𝐞𝐞𝐬 to Barcelona. 𝐎𝐯𝐞𝐫 5,000 𝐚𝐛𝐬𝐭𝐫𝐚𝐜𝐭𝐬 𝐰𝐞𝐫𝐞 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐛𝐲 600 𝐞𝐱𝐩𝐞𝐫𝐭 𝐬𝐩𝐞𝐚𝐤𝐞𝐫𝐬, offering the global oncology community a comprehensive look into the latest breakthroughs and trends in cancer research. 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥𝐬 𝐚𝐧𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐞𝐫𝐬 engaged in five days of rich discussions, cutting-edge presentations, and numerous interactions at the hundreds of pharma industry booths 𝐬𝐡𝐨𝐰𝐜𝐚𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐧𝐞𝐰𝐞𝐬𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬. With a festival-like atmosphere—complete with food trucks and lively networking events—this year's event was more than just a congress; it was a celebration of progress in oncology.   One key takeaway was that the potential of #AI 𝐢𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐢s remarkable. While there’s been a lot of hype, ESMO recognizes that 𝐀𝐈 𝐜𝐨𝐮𝐥𝐝 𝐭𝐫𝐮𝐥𝐲 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐚𝐫𝐞—from predictive analysis of patient data to digital imaging analysis with deep learning. This could reduce reliance on complex molecular testing and help us make more informed decisions. 𝐄𝐒𝐌𝐎 𝐢𝐬 𝐚𝐥𝐬𝐨 𝐥𝐚𝐮𝐧𝐜𝐡𝐢𝐧𝐠 𝐚 𝐝𝐞𝐝𝐢𝐜𝐚𝐭𝐞𝐝 𝐀𝐈 𝐚𝐧𝐝 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐢𝐧 2025 𝐭o help oncologists stay ahead of these advancements. #innovation #healthcare #oncology